VentriPoint Diagnostics Ltd (PK) (VPTDF)

Cardiac AI Diagnostics Stack Validation Wins Across Regulatory and Commercial FrontsMay 19, 2026 8:55 AM
PR Newswire (US) Issued on behalf of Ventripoint Diagnostics Ltd.A Toronto-based small-cap is converting clinical validation into real-world hospital deployments at the moment AI cardiac imaging procurement is reorganizing globallyNEW YORK, May 19, 2026 /PRNewswire/ -- USA News Group News Commentary — Cardiology has become one of the proving grounds for medical artificial intelligence, and the procurement environment around it has shifted hard in the last twelve months. Hospital networks are no longer content to evaluate clinical accuracy in isolation; they want department-level economic proof before they sign deployment contracts. That shift is reshaping which AI imaging companies can convert pilot data into recurring revenue, and which cannot. The companies winning right now are the ones stacking regulatory clearances, commercial partnerships, and reimbursement-friendly clinical evidence at the same time. Industry forecasts help frame the prize at stake. The artificial intelligence in cardiology market has been projected to grow from approximately US$2.78 billion in 2026 to roughly US$14.22 billion by 2034, representing a compound annual growth rate near 22.6% over the period.[1] Echocardiography alone — the most widely used cardiac imaging modality in the world — is forecast to expand to US$2.64 billion by 2030 as health systems demand cardiac platforms that prove economic value alongside clinical accuracy.[2]Read the full report of Ventripoint here: USA News Group Ventrpoint CoveragePortable ultrasound, valued at roughly US$2.79 billion in 2026, is pushing cardiac assessment beyond the imaging lab and into point-of-care settings where speed and cost efficiency determine which technologies earn long-term hospital contracts.[3]Inside that environment, Ventripoint Diagnostics Ltd. (TSXV: VPT) (OTC: VPTDF) has spent the first half of 2026 stringing together exactly the kinds of validation events that the new procurement environment rewards.The Toronto-headquartered company applies proprietary Knowledge Based Reconstruction technology to standard 2D echocardiograms and produces volumetric cardiac measurements that the company describes as equivalent in accuracy to magnetic resonance imaging — and it does so on ultrasound systems that already sit in hospitals worldwide, regardless of vendor.A Regulatory Submission Into the World's Largest Cardiac Disease PopulationOn April 28, 2026, Ventripoint announced that its strategic partner Lishman Global Inc. had formally submitted the Company's VMS+ 4.0 system to China's National Medical Products Administration (NMPA) — the regulatory body commonly referred to as the Chinese FDA — for approval.[4] The filing is the principal regulatory gating event for VMS+ access to the Chinese cardiology market, and according to the Company, Lishman Global qualified for the NMPA's "green channel" pathway, an expedited review process designed for innovative medical technologies that address significant clinical needs.[4]The scale of the opportunity is difficult to overstate. The Company has cited an estimated 330 million cardiovascular disease patients in China, with cardiovascular disease the leading cause of mortality in the country.[4]Echocardiography is already the most widely used cardiac imaging modality in China because of its cost-effectiveness, portability, and scalability across both urban and rural healthcare settings.[4] What the market has been short on, in Ventripoint's framing, is the kind of AI-driven analytic layer that produces consistent, MRI-equivalent volumetric measurements from those existing ultrasound exams — particularly given variability in image interpretation across operators and limited access to advanced modalities like MRI in many parts of the country."China is one of the most important cardiac care markets in the world," said Hugh MacNaught, President and Chief Executive Officer of Ventripoint Diagnostics, in the announcement. "With the benefit of an expedited review pathway, we are well positioned to bring VMS+ 4.0 to clinicians and patients more quickly."[4] Paul Gibson, Chief Technology Officer of Lishman Global, added that qualification for the NMPA's green channel "underscores the clinical relevance and innovation of VMS+ 4.0 and provides a clear pathway to accelerated adoption."[4]Read the full report of Ventripoint here: USA News Group Ventrpoint CoverageBringing AI Cardiac Imaging Into a Padua-Based European CongressSix days after the NMPA submission was announced, Ventripoint disclosed plans to exhibit at the 59th Annual Meeting of the Association for European Paediatric and Congenital Cardiology (AEPC), held May 12–16, 2026 in Padua, Italy.[5] Founded in 1963, AEPC is described as the world's largest association in congenital cardiology, bringing together more than 1,000 specialists across 32 European countries.[5]The 2026 meeting was hosted by the University of Padova and featured a scientific program centred on advanced cardiovascular imaging and artificial intelligence — a fit, the Company argued, for what VMS+ is designed to deliver.[5]A central focus of Ventripoint's booth at AEPC was the use of VMS+ to support evolution of cardiac function over time in congenital heart disease (CHD) patients. The clinical rationale, as the Company described it, sits inside the 2020 ESC Guidelines for Adult Congenital Heart Disease — guidelines co-endorsed by AEPC — which identify CHD as a lifelong chronic condition requiring structured, individualised follow-up, and which affirm echocardiography as the key modality for longitudinal assessment of ventricular function.[5] The latest release, VMS+ 4.0, was purpose-built around the workflow needs of clinicians, the Company has said, streamlining the time required to generate assessments and making volumetric cardiac analysis accessible at the point of care.[5]"AEPC represents the heart of the European congenital cardiology community, and we are proud to be part of it," MacNaught said in the AEPC announcement. "VMS+ delivers fast, affordable, and accessible volumetric cardiac assessments with accuracy comparable to MRI — giving clinicians the confidence they need to manage their patients at every stage of life."[5]A Wider Pattern of Validation Events Through Spring 2026The NMPA submission and AEPC exhibition are the two most recent links in a chain of events the Company has been building since the start of the year. Earlier in spring 2026, Ventripoint announced its Edison Award recognition, signed a commercial agreement with LG Consulting Solutions to support deployment of VMS+ across Northern California hospital systems, and announced a partnership delivering AI 3D heart mapping into Indigenous community settings through a Nisg_a'a partnership.[6]Considered together, those steps describe a small-cap AI medtech company simultaneously stacking validation across regulatory, commercial, and clinical fronts at the exact moment the broader hospital procurement environment is reorganizing around AI clinical solutions.[6]The LG Consulting Solutions agreement is structured precisely to address the financial proof requirement that has come to dominate hospital adoption decisions. Under the agreement, LG Consulting provides economic analysis, clinical implementation support, and health system business case development to assist hospitals and cardiac programs in adopting VentriPoint's AI-enhanced echocardiography technology.[6]In other words, the commercial framework on the ground in Northern California is designed to deliver department-level economic justification — which is exactly what hospital procurement is currently demanding before they sign.How Ventripoint Sits Inside a Reshaping Cardiac AI FieldVentripoint is far from the only public company chasing the AI cardiac imaging opportunity. Several larger names have moved aggressively across the past year — and the procurement environment for AI medtech is reshaping in real time as a result.Butterfly Network, Inc. (NYSE: BFLY) is one of the highest-profile names in handheld ultrasound. The Company has continued to expand integrations between its iQ family of probes and third-party AI cardiac applications, including the August 2025 announcement integrating Bordeaux-based DESKi's HeartFocus cardiac examination software into Butterfly's handheld devices — software that received FDA clearance in April 2025 and that allows healthcare professionals with minimal training to capture complete echocardiographic views.[7] Butterfly's strategy of partnering with AI cardiac software vendors places it in a structurally adjacent — but distinct — segment of the cardiac AI market from a knowledge-based reconstruction platform like Ventripoint's VMS+.Tempus AI, Inc. (NASDAQ: TEM) has been one of the cardiology AI sector's most-watched commercial stories. Tempus generated $1.2 billion in revenue for full-year 2025 and issued 2026 guidance of approximately $1.59 billion with around $65 million in adjusted EBITDA — projecting its first year of positive adjusted profitability.[1] Tempus's platform integrates genomic sequencing, clinical data analytics, and AI-driven insights across oncology, cardiology, and neuropsychiatric care — a substantially broader footprint than a pure-play cardiac imaging company, but one that frames the institutional investor appetite for AI medical platforms more generally. RadNet, Inc. (NASDAQ: RDNT) has built one of the larger imaging-services-plus-AI businesses through its DeepHealth subsidiary. RadNet's recent acquisition of Gleamer — whose products are deployed in over 2,000 facilities across 30 countries — uniquely positions DeepHealth to expand its impact across routine imaging and accelerate the delivery of automated diagnostics, with the combined entity projected to generate approximately $30 million in annualized recurring AI revenue in 2026.[1] RadNet's scale on the imaging-services side gives it a different kind of moat than a pure software vendor — but the strategic message about AI moving from pilot to recurring revenue is the same one playing out across the sector.GE HealthCare Technologies Inc. (NASDAQ: GEHC) brings the perspective of one of the world's largest installed bases of cardiac imaging equipment. GE HealthCare has been advancing its own cardiac imaging capabilities through AI-powered reconstruction technologies — including AIR Recon DL and Sonic DL — designed to deliver diagnostic-quality cardiac MRI scans in significantly reduced timeframes.[1]The fact that the largest incumbent in the space is investing aggressively in AI-augmented cardiac imaging is, if anything, supportive of the thesis that AI-enhanced echocardiography platforms like Ventripoint's are arriving into a market actively being reorganized around AI-driven clinical workflows. Across all four comparables, the same pattern shows up: hospital systems are demanding economic proof, AI cardiac imaging is shifting from pilot to recurring revenue, and AI-augmented echocardiography is increasingly viewed as the most leverageable cardiac modality given its existing scale, portability, and cost profile.What Comes NextVentripoint's near-term catalysts are reasonably visible. The NMPA review process for VMS+ 4.0 in China is now underway, and the Company has said it will provide further updates as the review process progresses.[4] On the commercial side, the LG Consulting Solutions deployment partnership in Northern California is set up to convert clinical evidence into hospital-level economic justification.[6] On the European side, the AEPC exhibition in Padua delivered direct engagement with the largest concentration of paediatric and congenital cardiologists in Europe — a clinical community uniquely well-suited to longitudinal echocardiography-driven follow-up of complex patients.[5]The Company's stated 2026 priority is accelerating the integration of VMS+ into routine clinical practice and identifying opportunities to build better care pathways for CHD patients.[5]For investors tracking the cardiac AI sector, the Company offers a small-cap exposure to a corner of the AI medtech market where the procurement environment, the regulatory environment, and the clinical evidence base have all moved into alignment within the past six months. Whether that alignment translates into accelerating commercial momentum will be measured one deployment, one NMPA decision, and one congress at a time across the back half of 2026.Read the full report of Ventripoint here: USA News Group Ventrpoint CoverageCONTACT INFORMATION
USA News Group
info @therooster-2873Article Sources
[1] https://www.fortunebusinessinsights.com/ai-in-cardiology-market-115767 [2] https://www.marketresearch.com/Business-Research-Company-v4006/Cardiac-AI-Monitoring-Diagnostics-Global-44014609/ [3] https://www.grandviewresearch.com/industry-analysis/artificial-intelligence-in-cardiology-market-report [4] https://finance.yahoo.com/sectors/healthcare/articles/ventripoints-vms-tm-4-0-120000052.html [5] https://finance.yahoo.com/sectors/healthcare/articles/ventripoint-exhibit-59th-annual-meeting-132316747.html [6] https://www.globenewswire.com/news-release/2026/05/13/3294035/0/en/A-Toronto-AI-Cardiac-Diagnostics-Company-Just-Cleared-Three-of-the-Hardest-Validation-Bars-in-Medtech.html [7] https://www.grandviewresearch.com/industry-analysis/artificial-intelligence-in-cardiology-market-reportDISCLAIMER NOTICENothing in this publication should be considered as personalized financial advice. We are not licensed under securities laws to address your particular financial situation. No communication by our employees to you should be deemed as personalized financial advice. Please consult a licensed financial advisor before making any investment decision. This is a paid advertisement and is neither an offer nor recommendation to buy or sell any security. We hold no investment licenses and are thus neither licensed nor qualified to provide investment advice. The content in this report or email is not provided to any individual with a view toward their individual circumstances. USA News Group is a wholly-owned subsidiary of Market IQ Media Group, Inc. (MIQ). This article is being distributed for Baystreet.ca media Corp, who has been paid a fee for an advertising campaign. MIQ has not been paid a fee for Ventripoint Diagnostics Ltd. advertising or digital media, but the owner/operators of MIQ also co-owns Baystreet.ca Media Corp. (BAY) There may also be 3rd parties who may have shares of Ventripoint Diagnostics Ltd. and may liquidate their shares which could have a negative effect on the price of the stock. This compensation constitutes a conflict of interest as to our ability to remain objective in our communication regarding the profiled company. Because of this conflict, individuals are strongly encouraged to not use this publication as the basis for any investment decision. The owner/operator of MIQ/BAY own shares of Ventripoint Diagnostics Ltd and reserve the right to buy and sell, and will buy and sell shares of Ventripoint Diagnostics Ltd. at any time without any further notice commencing immediately and ongoing. We also expect further compensation as an ongoing digital media effort to increase visibility for the company, no further notice will be given, but let this disclaimer serve as notice that all material, including this article, which is disseminated by MIQ on behalf of BAY has been approved by Ventripoint Diagnostics Ltd.; this is a paid advertisement, we currently own shares of Ventripoint Diagnostics Ltd. and will buy and sell shares of the company in the open market, or through private placements, and/or other investment vehicles. While all information is believed to be reliable, it is not guaranteed by us to be accurate. Individuals should assume that all information contained in our newsletter is not trustworthy unless verified by their own independent research. Also, because events and circumstances frequently do not occur as expected, there will likely be differences between the any predictions and actual results. Always consult a licensed investment professional before making any investment decision. Be extremely careful, investing in securities carries a high degree of risk; you may likely lose some or all of the investment.Logo - https://mma.prnewswire.com/media/2838876/5656770/USA_News_Group_Logo.jpg View original content to download multimedia:https://www.prnewswire.com/news-releases/cardiac-ai-diagnostics-stack-validation-wins-across-regulatory-and-commercial-fronts-302775850.htmlSOURCE USA News Group Original: Cardiac AI Diagnostics Stack Validation Wins Across Regulatory and Commercial Fronts

The $59B Quiet Shift Reshaping How Patients Access CareMay 12, 2026 10:30 AM
PR Newswire (US) Issued on behalf of VentriPoint Diagnostics Ltd.Equity-Insider.com News CommentaryVANCOUVER, BC, May 12, 2026 /PRNewswire/ -- Point-of-care diagnostics just crossed $58.76 billion globally in 2026, growing at nearly 10% annually as testing that used to require a hospital lab now fits on a clinic counter or a patient's nightstand[1]. That capital rotation is real: digital health startups pulled in $4 billion in Q1 alone, the strongest first quarter since the pandemic peak, with average deal sizes at levels not seen since late 2021[2]. Investors are not chasing drug discovery this cycle; they are backing companies that can deliver clinical-grade results through faster, lighter, cheaper channels, and five names sit at the center of that structural realignment: VentriPoint Diagnostics (TSXV: VPT) (OTCPK: VPTDF), Hims & Hers Health (NYSE: HIMS), Novo Nordisk (NYSE: NVO), MannKind (NASDAQ: MNKD), and Ginkgo Bioworks (NYSE: DNA).  The trajectory keeps steepening. Analysts project the global POC diagnostics market will reach $114.65 billion by 2035, fueled by AI integration, miniaturized biosensors, and cloud-connected platforms that compress turnaround times from days to minutes[3]. The entire diagnostic equipment value chain is shifting from a centralized hospital model to a decentralized, consumer-facing landscape, and that creates a scalable opening for platforms delivering accessible, clinical-grade outcomes outside traditional hospital walls.VentriPoint Diagnostics (TSXV: VPT) (OTCPK: VPTDF) is heading to Europe next week to showcase its AI-powered cardiac imaging platform at one of the biggest cardiology conferences on the planet. The company will exhibit at the 59th Annual Meeting of the Association for European Paediatric and Congenital Cardiology (AEPC), running May 12 to 16 in Padua, Italy, alongside European distributor AngioPro. AEPC is the world's largest association in congenital cardiology, with over 1,000 specialists across 32 countries, and this year's program is centered on cardiovascular imaging and artificial intelligence, exactly the areas where VentriPoint operates.VMS+™ 4.0 takes a standard 2D ultrasound scan and converts it into a detailed 3D model of the heart. The company says the results are comparable to cardiac MRI, but without the million-dollar machine or the months-long wait list. Built on more than a decade of proprietary Knowledge Based Reconstruction technology, the system works with ultrasound equipment from any manufacturer and holds regulatory approvals in the United States, Canada, and Europe.That regulatory footprint is expanding. In late April, VentriPoint announced that strategic partner Lishman Global Inc. formally submitted VMS+™ 4.0 to China's National Medical Products Administration (NMPA) for approval. Lishman Global qualified for the NMPA's expedited "green channel" review pathway, reserved for innovative technologies addressing significant clinical needs. China has an estimated 330 million patients affected by cardiovascular disease.Commercial momentum has been building. VentriPoint recently picked up a Gold Medal at the 2026 Edison Awards for VMS+™ 4.0. It announced a collaboration with the Health Division of the Montecristo Group to deploy VMS+™ across Costa Rica's hospital networks, where Hospital Metropolitano has an existing relationship with Sanford Health. VentriPoint also recently partnered with First Light Health to bring cardiac diagnostics to Indigenous and remote communities across Canada, building on an earlier partnership with the Nisga'a Valley Health Authority. The company also signed a commercial agreement with LG Consulting Solutions targeting cardiac centres in Northern California."AEPC represents the heart of the European congenital cardiology community, and we are proud to be part of it," said Hugh MacNaught, President and CEO of VentriPoint. "VMS+™ delivers fast, affordable, and accessible volumetric cardiac assessments with accuracy comparable to MRI, giving clinicians the confidence they need to manage their patients at every stage of life."With regulatory submissions advancing in China, distribution partners spanning Costa Rica to Northern California, Edison Award recognition, and a growing presence at major cardiology conferences, VentriPoint is building the kind of global footprint that turns a promising medtech platform into a scalable business.CONTINUED… Read this and more news for VentriPoint Diagnostics at: https://equity-insider.com/2025/11/21/the-mri-grade-disruption-hiding-in-plain-sight-why-the-smart-money-is-watching-ventripoint/Other industry developments and happenings in the market include:Hims & Hers Health (NYSE: HIMS) announced a new collaboration with Novo Nordisk to make a broad assortment of FDA-approved GLP-1 medications available to eligible customers, including Wegovy, the only FDA-approved GLP-1 weight loss pill. The expansion positions Hims & Hers Health as the largest global consumer health platform for affordable access to approved medications, with prices starting as low as $149 a month."Today we're taking an important next step toward building a better model of healthcare that works for everyday people," said Andrew Dudum, co-founder and CEO of Hims & Hers Health. "When healthcare innovators work together, we can make sure customer access moves at the same speed as innovation. As the largest global consumer health platform, we're thrilled to be working alongside Novo Nordisk to help more people feel their best and we're excited to find more ways to collaborate across the industry."Novo Nordisk (NYSE: NVO) is expanding patient reach through the partnership, with eligible customers now able to access treatments that can help them lose up to 20% of their body weight. Multiple Wegovy dosing options are available across both injectable and pill formats, alongside Ozempic injection pens approved for Type 2 diabetes treatment."Obesity medications have evolved over the last several years to become more affordable, more flexible, and more approachable for every kind of patient," said Dr. Craig Primack, SVP Weight Management at Hims & Hers Health. "As a part of our comprehensive treatment program, these FDA-approved medications will help more people get and stay healthy. We're excited to see how our customers succeed as more innovative treatments become available."MannKind (NASDAQ: MNKD) announced it will present new clinical data on Afrezza at the ATTD 2026 conference in Barcelona, spanning oral and poster sessions focused on real-world dosing patterns and post-prandial glucose management in both adult and pediatric patients with type 1 diabetes. The presentations include findings from the INHALE-1 study, which examined how inhaled insulin is initiated and adjusted in children and adolescents, with patients started at an approximately 2:1 conversion from rapid-acting insulin analogs."We look forward to presenting important new data for Afrezza at this year's ATTD and contributing to the scientific dialogue around meal-time diabetes management across both adult and pediatric populations," said Kevin Kaiserman, MD, Senior Vice President, Therapeutic Area Head, Diabetes for MannKind. "ATTD is a key forum for advancing how clinicians think about insulin use at meals, and we value the opportunity to engage with the global diabetes community on this important topic."The FDA accepted a supplemental Biologics License Application for Afrezza in patients ages 4-17 living with type 1 or type 2 diabetes, with a PDUFA target action date of May 29, 2026. If approved, Afrezza would become the first needle-free insulin option for pediatric patients in over 100 years.Ginkgo Bioworks (NYSE: DNA) launched Ginkgo Cloud Lab, a browser-based interface that gives researchers remote access to the company's autonomous lab infrastructure powered by proprietary Reconfigurable Automation Carts. The platform connects scientists to a fleet of over 70 instruments spanning sample preparation, liquid handling, analytical readouts, storage, and incubation, with an AI-driven agent called EstiMate enabling protocol submission in plain language and immediate compatibility assessment and pricing."Autonomous labs are poised to scale and accelerate the high-mix work that a lab bench supports," said Jason Kelly, CEO of Ginkgo Bioworks. "By opening up our autonomous infrastructure through the Cloud Lab, we're giving scientists access to these tools today."Ginkgo Cloud Lab is central to Ginkgo Bioworks' 2026 strategic shift to consolidate all R&D services onto Nebula, its autonomous lab in Boston, MA, decommissioning traditional benches in favor of programmable robotic infrastructure. The company is targeting users ranging from academic researchers to global biopharmaceutical companies, inviting them to submit protocols directly at cloud.ginkgo.bio for feasibility reports and price quotes.Further Reading: https://equity-insider.com/2025/11/21/the-mri-grade-disruption-hiding-in-plain-sight-why-the-smart-money-is-watching-ventripoint/CONTACT:
Equity Insider
info @acblanke1DISCLAIMER: Nothing in this publication should be considered as personalized financial advice. We are not licensed under securities laws to address your particular financial situation. No communication by our employees to you should be deemed as personalized financial advice. Please consult a licensed financial advisor before making any investment decision. This is a paid advertisement and is neither an offer nor recommendation to buy or sell any security. We hold no investment licenses and are thus neither licensed nor qualified to provide investment advice. The content in this report or email is not provided to any individual with a view toward their individual circumstances. Equity Insider is a wholly-owned subsidiary of Market IQ Media Group, Inc. (MIQ). This article is being distributed for Baystreet.ca media Corp, who has been paid a fee for an advertising campaign. MIQ has not been paid a fee for Ventripoint Diagnostics Ltd. advertising or digital media, but the owner/operators of MIQ also co-owns Baystreet.ca Media Corp. (BAY) There may also be 3rd parties who may have shares of Ventripoint Diagnostics Ltd. and may liquidate their shares which could have a negative effect on the price of the stock. This compensation constitutes a conflict of interest as to our ability to remain objective in our communication regarding the profiled company. Because of this conflict, individuals are strongly encouraged to not use this publication as the basis for any investment decision. The owner/operator of MIQ/BAY own shares of Ventripoint Diagnostics Ltd and reserve the right to buy and sell, and will buy and sell shares of Ventripoint Diagnostics Ltd. at any time without any further notice commencing immediately and ongoing. We also expect further compensation as an ongoing digital media effort to increase visibility for the company, no further notice will be given, but let this disclaimer serve as notice that all material, including this article, which is disseminated by MIQ on behalf of BAY has been approved by Ventripoint Diagnostics Ltd.; this is a paid advertisement, we currently own shares of Ventripoint Diagnostics Ltd. and will buy and sell shares of the company in the open market, or through private placements, and/or other investment vehicles. While all information is believed to be reliable, it is not guaranteed by us to be accurate. Individuals should assume that all information contained in our newsletter is not trustworthy unless verified by their own independent research. Also, because events and circumstances frequently do not occur as expected, there will likely be differences between the any predictions and actual results. Always consult a licensed investment professional before making any investment decision. Be extremely careful, investing in securities carries a high degree of risk; you may likely lose some or all of the investment.SOURCES:https://www.mordorintelligence.com/industry-reports/point-of-care-diagnosticshttps://www.medtechdive.com/news/digital-health-funding-concentrates-fewer-startups-q1-2026-rock-health/816933/ https://www.globenewswire.com/news-release/2026/04/30/3285062/0/en/Global-Point-of-Care-Diagnostics-Market-Size-Set-to-Reach-USD-114-65-Billion-by-2035-SNS-Insider.html Logo: https://mma.prnewswire.com/media/2840019/Equity_Insider_Logo.jpg View original content:https://www.prnewswire.com/news-releases/the-59b-quiet-shift-reshaping-how-patients-access-care-302769492.html Original: The $59B Quiet Shift Reshaping How Patients Access Care

Why Medtech Giants Are Quietly Paying Up for AI DiagnosticsApril 29, 2026 10:30 AM
PR Newswire (Canada)

ISSUED ON BEHALF OF VENTRIPOINT DIAGNOSTICS LTD.VANCOUVER, BC, April 29, 2026 /CNW/ -- USANewsGroup.com News Commentary – There's a quiet bidding war underway for AI diagnostics, and the price keeps climbing. The global AI in medical imaging market is on track to hit $2.20 billion in 2026, with a 34.8% growth rate baked in through 2033[1]. Q1 2026 healthcare M&A activity tells the same story: capital is rotating into AI-enabled platforms that already carry regulatory clearance, recurring revenue, and real clinical data behind them[2]. That description fits a short list of names worth knowing right now: VentriPoint Diagnostics (TSXV: VPT) (OTCPK: VPTDF), Medtronic (NYSE: MDT), Danaher (NYSE: DHR), Profound Medical (NASDAQ: PROF), and DexCom (NASDAQ: DXCM).







Hospitals are voting with their wallets too. A fresh C-suite survey shows 57% now rank AI clinical solutions as their top technology priority for 2026 to 2027, up from just 19% in 2023[3]. The FDA has made it clear that real-world clinical evidence is now central to clearing AI software, which is exactly why institutional buyers are paying a clinical validation premium for platforms that already have multi-site data behind them[4].VentriPoint Diagnostics (TSXV: VPT) (OTCPK: VPTDF) just picked up a Gold Medal at the 2026 Edison Awards for its AI-powered cardiac imaging platform, VMS+™ 4.0. The Edison Awards are widely considered one of the most prestigious innovation prizes in the world, often called "the Oscars of Innovation," and past Gold winners include Abbott, Medtronic, and Boston Scientific. For a small-cap medtech company out of Toronto, that is serious company to keep.The technology behind the award takes a standard 2D ultrasound scan and converts it into a detailed 3D model of the heart. The company says the results are comparable to a cardiac MRI, but without the million-dollar machine or the months-long wait list. VMS+™ 4.0 is already deployed in hospitals across the United States, Canada, the United Kingdom, and Europe, which is a key reason the Edison judges took notice. Their evaluation process places heavy weight on technologies that have moved past the pilot stage and into real clinical use.That momentum is showing up in VentriPoint's commercial pipeline. The company recently announced a collaboration with the Health Division of the Montecristo Group to roll out VMS+™ across Costa Rica's public and private hospital networks. The Montecristo Group's Hospital Metropolitano also has an existing relationship with Sanford Health, one of the largest healthcare systems in the United States. VentriPoint also recently partnered with First Light Health, an Indigenous-owned medical services company, to bring cardiac diagnostics to Indigenous and remote communities across Canada through a hub-and-spoke model. That program builds on an earlier partnership with the Nisga'a Valley Health Authority in northern BC. South of the border, the company signed a commercial agreement with LG Consulting Solutions targeting cardiac centres in Northern California."Being awarded Gold affirms that VMS™ 4.0 has reached that threshold, and reinforces our belief that our platform has significant room to grow as adoption accelerates and new applications emerge," said Hugh MacNaught, CEO of VentriPoint.VentriPoint holds regulatory approvals in the United States, Canada, and Europe. Its VMS+™ platform is vendor-agnostic, meaning it works with ultrasound equipment from any manufacturer, and is built on more than a decade of proprietary Knowledge Based Reconstruction technology. The core value proposition is MRI-grade cardiac imaging at a fraction of the cost, deployable anywhere a standard ultrasound machine already sits. With a growing global footprint, a validated technology platform, and independent recognition from one of the world's top innovation bodies, VentriPoint is positioning itself as a name to watch in precision health.CONTINUED… Read this and more news for VentriPoint Diagnostics at:  https://usanewsgroup.com/2025/11/21/the-mri-grade-disruption-hiding-in-plain-sight-why-the-smart-money-is-watching-ventripointOther industry developments and happenings in the market include:Medtronic (NYSE: MDT) completed its acquisition of CathWorks, a privately held medical device company focused on coronary artery disease diagnosis and treatment, for $585 million with potential additional earn-out payments. The deal follows a 2022 co-promotion agreement and brings the CathWorks FFRangio System, an AI-powered, drug-free, wire-free coronary assessment platform, into Medtronic's interventional cardiology portfolio."The acquisition of CathWorks significantly enhances Medtronic's interventional cardiology portfolio with an innovative system that empowers physicians with data-driven insights for the diagnosis and treatment of coronary artery disease," said Jason Weidman, senior vice president and president of the Coronary & Renal Denervation business, part of the Cardiovascular Portfolio at Medtronic. "Through our global footprint, welcoming CathWorks to Medtronic will expand access to the transformative FFRangio technology for our customers and their patients worldwide."The FFRangio System recently demonstrated non-inferiority to wire-based physiology in the ALL-RISE randomized control trial, which enrolled more than 1,900 patients across 59 sites globally. The acquisition is expected to be immaterial to Medtronic's fiscal year 2027 earnings and neutral to accretive thereafter, continuing the company's strategy of targeted tuck-in acquisitions to strengthen its core franchises.Danaher (NYSE: DHR) reported first quarter 2026 results showing revenues of $6.0 billion, up 3.5% year-over-year, with non-GAAP adjusted diluted EPS growing 9.5% to $2.06. Operating cash flow reached $1.3 billion, supported by strength in Bioprocessing and better-than-expected Life Sciences performance."Our team executed well in the first quarter, which enabled us to accelerate innovation, drive productivity gains, and deliver nearly 10% adjusted EPS growth," said Rainer M. Blair, President and CEO of Danaher. "On the top line, we continued on a steady recovery path with strength in Bioprocessing and better-than-expected performance in Life Sciences largely offsetting the impact of a lighter-than-typical Q1 respiratory season at Cepheid."Danaher raised its full year 2026 adjusted diluted EPS guidance to $8.35 to $8.55, up from prior guidance of $8.35 to $8.50, and expects full year core revenue growth of 3% to 6%. The company also announced its intention to acquire Masimo Corporation, a provider of pulse oximetry and patient monitoring solutions, citing opportunities to enhance performance through the Danaher Business System and its global scale.Profound Medical (NASDAQ: PROF) is highlighting its TULSA-PRO system across seven presentations at the 2026 Society of Interventional Radiology Annual Scientific Meeting in Toronto, April 11-15. The commercial-stage medical device company's AI-powered, MRI-guided TULSA Procedure treats prostate cancer and benign prostatic hyperplasia without incisions, eliminating procedural blood loss and overnight hospital stays while minimizing side effects such as urinary incontinence and erectile dysfunction."Our significant presence at SIR 2026 comes at an opportune time as leading iMRI procedures, including MRI-guided biopsy and TULSA, are poised to transform how unmet medical needs across the prostate disease spectrum are being addressed," said Arun Menawat, CEO and Chairman of Profound Medical. "Awareness and acceptance of the TULSA Procedure's strong clinical profile, as well as its potential to become the next mainstream treatment modality for most men with prostate disease, is growing."Presentations will feature data from the Level 1 post-market CAPTAIN randomized controlled trial comparing TULSA against robotic prostatectomy for intermediate-risk prostate cancer. Profound Medical also commercializes Sonalleve, an MRI-guided therapy addressing bone metastases pain palliation, uterine fibroids, and adenomyosis, with its technologies approved across major global markets including the United States, Europe, and Canada.DexCom (NASDAQ: DXCM) is showcasing new clinical evidence at the 19th annual Advanced Technologies and Treatments for Diabetes Conference in Barcelona, reinforcing the role of continuous glucose monitoring across all diabetes types. A multi-center primary care registry study showed that after one year of Dexcom G7 use, people with Type 2 diabetes not on insulin therapy saw significant improvements in A1C and weight management, while claims data linked Dexcom CGM initiation to meaningful reductions in DKA-related hospitalizations and emergency room visits in both children and adults with Type 1 diabetes."There is no better global stage than ATTD to showcase how we're shaping the future of glucose biosensing around the world," said Jake Leach, president and chief executive officer at DexCom. "The data presented at ATTD reinforces the need for Dexcom CGM to become the standard of care for all people with Type 2 diabetes, including those not using insulin."Beyond the clinical data, DexCom is presenting its near- and long-term product roadmap, including upcoming features for Dexcom G7, Dexcom G7 15 Day, and Stelo, its health and wellness offering. The company recently launched Dexcom G7 15 Day in the U.S. and continues expanding its Dexcom Academy HCP education platform across Europe and the Middle East.Further Reading: https://usanewsgroup.com/2025/11/21/the-mri-grade-disruption-hiding-in-plain-sight-why-the-smart-money-is-watching-ventripointCONTACT:
USA NEWS GROUP
info @acblanke1DISCLAIMER: Nothing in this publication should be considered as personalized financial advice. We are not licensed under securities laws to address your particular financial situation. No communication by our employees to you should be deemed as personalized financial advice. Please consult a licensed financial advisor before making any investment decision. This is a paid advertisement and is neither an offer nor recommendation to buy or sell any security. We hold no investment licenses and are thus neither licensed nor qualified to provide investment advice. The content in this report or email is not provided to any individual with a view toward their individual circumstances. USA News Group is a wholly-owned subsidiary of Market IQ Media Group, Inc. (MIQ). This article is being distributed for Baystreet.ca media Corp, who has been paid a fee for an advertising campaign. MIQ has not been paid a fee for Ventripoint Diagnostics Ltd. advertising or digital media, but the owner/operators of MIQ also co-owns Baystreet.ca Media Corp. (BAY) There may also be 3rd parties who may have shares of Ventripoint Diagnostics Ltd. and may liquidate their shares which could have a negative effect on the price of the stock. This compensation constitutes a conflict of interest as to our ability to remain objective in our communication regarding the profiled company. Because of this conflict, individuals are strongly encouraged to not use this publication as the basis for any investment decision. The owner/operator of MIQ/BAY own shares of Ventripoint Diagnostics Ltd and reserve the right to buy and sell, and will buy and sell shares of Ventripoint Diagnostics Ltd. at any time without any further notice commencing immediately and ongoing. We also expect further compensation as an ongoing digital media effort to increase visibility for the company, no further notice will be given, but let this disclaimer serve as notice that all material, including this article, which is disseminated by MIQ on behalf of BAY has been approved by Ventripoint Diagnostics Ltd.; this is a paid advertisement, we currently own shares of Ventripoint Diagnostics Ltd. and will buy and sell shares of the company in the open market, or through private placements, and/or other investment vehicles. While all information is believed to be reliable, it is not guaranteed by us to be accurate. Individuals should assume that all information contained in our newsletter is not trustworthy unless verified by their own independent research. Also, because events and circumstances frequently do not occur as expected, there will likely be differences between the any predictions and actual results. Always consult a licensed investment professional before making any investment decision. Be extremely careful, investing in securities carries a high degree of risk; you may likely lose some or all of the investment.SOURCES:https://www.coherentmarketinsights.com/industry-reports/ai-in-medical-imaging-market https://www.sikich.com/insight/q1-2026-healthcare-ma-market-update/ https://hitconsultant.net/2026/03/24/sage-growth-partners-health-it-purchasing-forecast-2026-2027-ai-roi/ https://www.fda.gov/news-events/fda-voices/real-world-evidence-advancing-regulatory-decision-making-medical-devices Logo - https://mma.prnewswire.com/media/2838876/5919929/USA_News_Group_Logo.jpg



View original content to download multimedia:https://www.prnewswire.com/news-releases/why-medtech-giants-are-quietly-paying-up-for-ai-diagnostics-302757277.html

Original: Why Medtech Giants Are Quietly Paying Up for AI Diagnostics

Upcoming Meeting Dates - March 23, 2026March 23, 2026 12:00 AM
NewsfileToronto, Ontario--(Newsfile Corp. - March 23, 2026) - The following is a list of Upcoming Meeting Dates announced this week for Reporting Issuers in Canada. The data is supplied by Issuing Companies through the service of CDS Clearing and Depository Services Inc.CompanyRecord DateMeeting DateType Aecon Group Inc April 9, 2026June 1, 2026AG  Argyle Resources Corp. April 7, 2026May 12, 2026AS  B2Gold Corp. *April 13, 2026June 4, 2026AGS Ballard Power Systems Inc. April 6, 2026June 3, 2026A  Big Rock Brewery Inc. April 10, 2026May 20, 2026A  Black Pearl Resources Corp. March 18, 2026April 9, 2026S  CATHEDRA BITCOIN INC. March 25, 2026May 15, 2026S  COSCIENS Biopharma Inc. %March 3, 2026April 7, 2026S  CULT Food Science Corp. %February 19, 2026April 6, 2026AS  Cambria Gold Mines Inc April 10, 2026May 27, 2026AGS Canso Select OpportunitiesCorpApril 7, 2026May 26, 2026A  CareRx Corporation April 8, 2026May 28, 2026AG  Cascades Inc. March 25, 2026May 8, 2026AG  AGF China Focus Class April 2, 2026May 14, 2026S  Centaurus Energy Inc. April 10, 2026May 25, 2026A  Cloud3 Ventures Inc. *March 4, 2026April 16, 2026S  DATA Communications ManagementApril 6, 2026May 21, 2026AGS DiagnosTear Technologies Inc. *March 16, 2026May 7, 2026A  Dream Impact Trust April 10, 2026June 3, 2026AG  Dream Industrial REIT April 10, 2026June 3, 2026AS  Dream Office REIT April 10, 2026June 3, 2026AG  Dream Unlimited Corp. April 10, 2026June 3, 2026AG  Endeavour Silver Corp April 10, 2026June 2, 2026AG  Euromax Resources Ltd April 15, 2026May 22, 2026AG  Everybody Loves Languages Corp*January 27, 2026March 26, 2026AGS NCM Core international April 2, 2026May 15, 2026S  Canadian Net REIT April 6, 2026May 26, 2026A  GRANDE PORTAGE RESOURECES INC April 10, 2026May 15, 2026A  Gold Strike Resources Inc. March 24, 2026April 30, 2026S  Granite REIT April 9, 2026June 4, 2026A  MTY Food Group Inc April 7, 2026May 20, 2026AG  Highwood Asset Management Ltd.April 6, 2026May 21, 2026AS  INTL Tower Hill Mines Ltd April 8, 2026May 27, 2026AG  KITS Eyecare Ltd. April 16, 2026June 3, 2026AG  Kaymus Resources Inc. April 10, 2026May 22, 2026AGS LI-FT POWER LTD April 7, 2026May 15, 2026A  Dorel Industries Inc. April 7, 2026May 20, 2026AG  LunR Royalties Corp. April 7, 2026May 21, 2026AGS Luxxfolio Holdings Inc. April 7, 2026May 12, 2026A  MARIMED INC. April 10, 2026June 4, 2026A  Mercer Park Opportunities Corp*February 27, 2026April 14, 2026S  MineHub Technologies Inc. April 10, 2026May 25, 2026A  Morien Resources Corp April 8, 2026May 13, 2026AGS Norse Gold Corp April 7, 2026May 13, 2026AS  Northland Power Inc. April 6, 2026May 20, 2026AG  Osisko Metals Incorporated April 7, 2026May 28, 2026A  P2 Gold Inc. April 9, 2026May 27, 2026AS  Parkit Enterprise Inc. April 8, 2026May 21, 2026AGS Perpetua Resources Corp. April 8, 2026June 4, 2026AG  PesoRama Inc. April 6, 2026May 7, 2026AS  Petrus Resources Ltd. April 6, 2026May 21, 2026A  Pinetree Capital Ltd. April 8, 2026May 28, 2026A  NCM Global Eq Balanced PortfolioApril 2, 2026May 15, 2026S  NCM Global Inc Bal Portfolio April 2, 2026May 15, 2026S  Profound Medical Corp. April 2, 2026May 13, 2026AGS Purepoint Uranium Group Inc. April 15, 2026June 4, 2026AS  Rua Gold Inc. April 8, 2026May 28, 2026AGS SAVANNA CAPITAL CORP. April 13, 2026May 21, 2026AGS STLLR GOLD INC April 9, 2026May 27, 2026A  Saturn Oil & Gas Inc. April 6, 2026May 21, 2026AS  Seabridge Gold Inc. March 30, 2026May 22, 2026S  Sierra Madre Gold and Silver Ltd.March 24, 2026April 28, 2026S  Stampede Drilling Inc. April 7, 2026May 14, 2026A  StorageVault Canada Inc. April 7, 2026May 21, 2026AG  Swiss Water Decaffeinated CoffeeApril 13, 2026May 21, 2026AGS TSODILO RESOURCES LIMITED April 17, 2026May 29, 2026AG  TerrAscend Corp. April 13, 2026June 9, 2026A  The Westaim Corporation April 9, 2026May 19, 2026AGS Tidewater Midstream And InfrastructureApril 6, 2026May 26, 2026AG  Tidewater Renewables Ltd. April 6, 2026May 26, 2026AG  Tincorp Metals Inc. April 1, 2026May 5, 2026AS  Trojan Gold Inc. April 6, 2026May 11, 2026AS  Valory Resources Inc. April 13, 2026June 2, 2026AG  Ventripoint Diagnostics Ltd April 8, 2026May 27, 2026AS  Vireo Growth Inc. April 7, 2026May 29, 2026AS  Vox Royalty Corp. April 10, 2026May 27, 2026AS  Legend:* = Change in Previously Reported Information
% = Cancelled Meeting
@ = Adjourned MeetingType of MeetingA = Annual Meeting
S = Special Meeting
G = General Meeting
B = Bondholder Meeting
C = Court Meeting For more information, please visit https://www.cds.ca/ To view the source version of this press release, please visit https://www.newsfilecorp.com/release/289185
Original: Upcoming Meeting Dates - March 23, 2026

Hospital Networks Turn to AI-Enhanced Cardiac Imaging to Cut Costs and Improve OutcomesMarch 3, 2026 12:19 PM
PR Newswire (US)

Issued on behalf of VentriPoint Diagnostics Ltd.VANCOUVER, BC, March 3, 2026 /PRNewswire/ -- USANewsGroup.com News Commentary — AI is making its way through the halls of our entire medical system, and the implementation is accelerating at a great pace. The AI medical imaging market is projected to hit nearly $20 billion by 2033, growing at a 34.7% CAGR[1]. Echocardiography alone is forecast to grow to $2.64 billion by 2030 as hospitals demand cardiac platforms that prove economic value alongside clinical accuracy[2]. Companies like VentriPoint Diagnostics (TSXV: VPT) (OTCPK: VPTDF), Butterfly Network (NYSE: BFLY), Tempus AI (NASDAQ: TEM), RadNet (NASDAQ: RDNT), and GE HealthCare (NASDAQ: GEHC) are converting clinical validation into contracted hospital deployments.







Digital diagnostics platforms are projected to reach $7.67 billion by 2035 at an 18.12% CAGR as health systems shift from evaluating clinical capability to requiring department-level financial proof before adoption[3]. Portable ultrasound, valued at $2.79 billion in 2026, is pushing cardiac assessment beyond traditional imaging labs and into point-of-care settings where speed and cost efficiency determine which technologies earn long-term hospital contracts[4].VentriPoint Diagnostics (TSXV: VPT) (OTCPK: VPTDF) recently signed a commercial agreement with LG Consulting Solutions to support deployment of its VMS+™ system across Northern California. Under the agreement, LG Consulting will provide economic analysis, clinical implementation support, and health system business case development to assist hospitals and cardiac programs in adopting VentriPoint's AI-enhanced echocardiography technology. The collaboration will focus on demonstrating the economic and clinical value of VMS+™ imaging and workflow integration across healthcare systems in the Sacramento and San Francisco regions.As part of the agreement, LG Consulting Solutions is purchasing a VMS+™ system for deployment as a demonstration platform to support hospital engagement, clinician training, and economic value assessments. The agreement also includes the potential for revenue sharing related to 3D echocardiography processing services."Economic and operational clarity are critical to accelerating the adoption of new medical technologies," said Hugh MacNaught, President and CEO of VentriPoint Diagnostics. "This collaboration will help hospitals clearly evaluate how VMS+™ can improve cardiac care pathways, enhance clinical insight into cardiac function, and support better patient care while delivering measurable value to healthcare systems."Northern California represents an important market for VentriPoint given its concentration of leading cardiac centers and healthcare systems focused on improving cardiovascular outcomes."Healthcare systems increasingly require clear clinical and economic evidence before adopting new technologies," said Lori Gallian, Principal of LG Consulting. "Through this collaboration, we will work directly with cardiac programs to develop practical implementation strategies and demonstrate how VMS+™ can deliver both clinical and operational benefits."CONTINUED… Read this and more news for VentriPoint Diagnostics at: https://usanewsgroup.com/2025/11/21/the-mri-grade-disruption-hiding-in-plain-sight-why-the-smart-money-is-watching-ventripoint In other industry developments and happenings in the market include:Butterfly Network (NYSE: BFLY) recently reported fourth quarter 2025 revenue of $31.5 million, a 41% increase year-over-year, while generating positive operating cash flow for the first time in the company's history. Full-year 2025 revenue reached $97.6 million, up 19% from the prior year. The company also launched Compass, its AI-powered clinical decision support system designed to guide clinicians through point-of-care ultrasound exams." Nearly two years into our strategic plan, we are executing with financial discipline, strengthening our core point-of-care business, and now realizing material organic revenue from new initiatives," said Joseph DeVivo, CEO of Butterfly Network. "From expanding enterprise adoption in point-of-care, to building HomeCare into a commercial business, to enabling entirely new applications through Butterfly Embedded, it's all powered by the same proprietary Ultrasound-on-Chip™ technology. One platform and one diversified strategy that puts us in a strong position to execute and win."The company issued 2026 revenue guidance of $117 million to $121 million, representing 20% to 24% growth. Butterfly's handheld ultrasound platform is used across emergency, primary care, and critical care settings, expanding cardiac and vascular assessment beyond traditional imaging labs.Tempus AI (NASDAQ: TEM) recently reported fourth quarter 2025 revenue of $367.2 million, an 83% increase year-over-year. For the full year, Tempus generated $1.2 billion in revenue and issued 2026 guidance of approximately $1.59 billion with around $65 million in adjusted EBITDA, projecting its first year of positive adjusted profitability."In 2025, Tempus continued to set the standard for what it means to be a technology company operating in the healthcare space," said Eric Lefkofsky, Founder and CEO of Tempus. "The strength of our unit growth in diagnostics along with the accelerating growth of our data business is proof that we are unique in this space. As the network effects from our investments in AI continue to compound, we expect to not only drive significant growth over the next several years, but to also enhance the lives of millions of patients around the world."The company's platform integrates genomic sequencing, clinical data analytics, and AI-driven insights across oncology, cardiology, and neuropsychiatry. Tempus serves more than 50% of U.S. oncologists and is expanding its data licensing and clinical trial matching capabilities into cardiovascular diagnostics.RadNet (NASDAQ: RDNT) recently acquired Gleamer, a Paris-based pioneer in AI-powered medical imaging, for up to €230 million. The acquisition positions RadNet's DeepHealth subsidiary as the largest radiology-focused clinical AI provider worldwide, combining Gleamer's BoneView and ChestView FDA-cleared algorithms with DeepHealth's existing suite of mammography, lung, and prostate AI solutions."As imaging volumes continue to rise amid an accelerating shortage of radiologists worldwide, reengineering high-volume workflows — particularly routine imaging such as X-ray, ultrasound and mammography — is becoming essential to sustaining access, efficiency and quality of care," said Dr. Howard Berger, President and CEO of RadNet. "For radiologists and providers, the key lies in advancing automated exam prioritization and draft reporting. The acquisition of Gleamer uniquely positions DeepHealth to expand its impact across routine imaging and high-impact acute diagnostic care and accelerate the delivery of automated diagnostics."Gleamer's products are deployed in over 2,000 facilities across 30 countries. The combined entity is projected to generate approximately $30 million in annualized recurring AI revenue in 2026, with commercial deployment spanning bone fracture detection, chest pathology screening, and advanced mammography analytics.GE HealthCare (NASDAQ: GEHC) recently announced the first implementation of its SIGNA Sprint Elite MRI system at Inova Health System. The platform integrates advanced cardiac imaging capabilities with AI-powered reconstruction technologies including AIR Recon DL and Sonic DL, designed to deliver diagnostic-quality cardiac MRI scans in significantly reduced timeframes."Achieving FDA clearance of our next-generation SIGNA MRI technology underscores our commitment to expanding access to high-quality imaging and elevating the standard of care for patients everywhere," said Kelly Londy, President and CEO, MR at GE HealthCare. "As MRI demand continues to rise across clinical areas, providers need solutions that deliver greater efficiency without compromising diagnostic precision. With this new SIGNA generation, we're redefining what's possible – aiming to bring smarter, faster, more sustainable and more consistent imaging to more patients, across more settings, with confidence."The SIGNA Sprint Elite features a compact 22-square-meter footprint, allowing installation in outpatient and community settings previously limited to basic imaging. GE HealthCare's broader imaging portfolio serves more than 1 billion patients annually across 160 countries, with its MR division focused on expanding AI-integrated cardiac and neurological imaging platforms.Article Source: https://usanewsgroup.com/2025/11/21/the-mri-grade-disruption-hiding-in-plain-sight-why-the-smart-money-is-watching-ventripoint CONTACT:USA NEWS GROUPinfo @acblanke1DISCLAIMER: Nothing in this publication should be considered as personalized financial advice. We are not licensed under securities laws to address your particular financial situation. No communication by our employees to you should be deemed as personalized financial advice. Please consult a licensed financial advisor before making any investment decision. This is a paid advertisement and is neither an offer nor recommendation to buy or sell any security. We hold no investment licenses and are thus neither licensed nor qualified to provide investment advice. The content in this report or email is not provided to any individual with a view toward their individual circumstances. USA News Group is a wholly-owned subsidiary of Market IQ Media Group, Inc. ("MIQ"). This article is being distributed for Baystreet.ca media Corp, who has been paid a fee for an advertising campaign. MIQ has not been paid a fee for Ventripoint Diagnostics Ltd. advertising or digital media, but the owner/operators of MIQ also co-owns Baystreet.ca Media Corp. ("BAY") There may also be 3rd parties who may have shares of Ventripoint Diagnostics Ltd. and may liquidate their shares which could have a negative effect on the price of the stock. This compensation constitutes a conflict of interest as to our ability to remain objective in our communication regarding the profiled company. Because of this conflict, individuals are strongly encouraged to not use this publication as the basis for any investment decision. The owner/operator of MIQ/BAY own shares of Ventripoint Diagnostics Ltd and reserve the right to buy and sell, and will buy and sell shares of Ventripoint Diagnostics Ltd. at any time without any further notice commencing immediately and ongoing. We also expect further compensation as an ongoing digital media effort to increase visibility for the company, no further notice will be given, but let this disclaimer serve as notice that all material, including this article, which is disseminated by MIQ on behalf of BAY has been approved by Ventripoint Diagnostics Ltd.; this is a paid advertisement, we currently own shares of Ventripoint Diagnostics Ltd. and will buy and sell shares of the company in the open market, or through private placements, and/or other investment vehicles. While all information is believed to be reliable, it is not guaranteed by us to be accurate. Individuals should assume that all information contained in our newsletter is not trustworthy unless verified by their own independent research. Also, because events and circumstances frequently do not occur as expected, there will likely be differences between the any predictions and actual results. Always consult a licensed investment professional before making any investment decision. Be extremely careful, investing in securities carries a high degree of risk; you may likely lose some or all of the investment.SOURCES:https://www.grandviewresearch.com/industry-analysis/artificial-intelligence-medical-imaging-markethttps://www.precedenceresearch.com/echocardiography-markethttps://www.towardshealthcare.com/insights/digital-diagnostics-system-market-sizinghttps://www.towardshealthcare.com/insights/portable-ultrasound-market-sizingLogo: https://mma.prnewswire.com/media/2838876/5833576/USA_News_Group_Logo.jpg



View original content to download multimedia:https://www.prnewswire.com/news-releases/hospital-networks-turn-to-ai-enhanced-cardiac-imaging-to-cut-costs-and-improve-outcomes-302702775.html

Original: Hospital Networks Turn to AI-Enhanced Cardiac Imaging to Cut Costs and Improve Outcomes

CEO.CA's Inside the Boardroom: Why Ventripoint is the Most Profitable "Bolt-On" Solution for Modern HospitalsFebruary 26, 2026 12:10 PM
NewsfileToronto, Ontario--(Newsfile Corp. - February 26, 2026) - CEO.CA ("CEO.CA"), the leading investor social network in junior resource and venture stocks, shares exclusive updates with CEOs of junior mining explorers.Founded in 2012, CEO.CA, a wholly owned subsidiary of EarthLabs, Inc., is one of the most popular free financial websites and apps in Canada and for investors globally - with industry leading audience engagement and mobile functionality. Millions of people visit CEO.CA each year to connect with investors from around the world, share knowledge and view impactful stories about stocks, commodities, and emerging companies.Meet the Executive Shaping the Biotechnology Landscape'Inside the Boardroom' is more than just an interview series - it's a chance to gain firsthand knowledge from industry leaders, understanding their vision, challenges, and strategy.Most life-saving medical tech fails because it cannot prove its value to hospital executives. In this interview, Dana Friesen of Summit Sciences Inc. breaks down the "Patient Turnover" advantage of Ventripoint Diagnostics Ltd. (TSXV: VPT). He explains how the VMS+ system eliminates the 4 to 5 day wait for cardiac MRIs, potentially saving hospitals up to $40,000 per scan in bed-day costs. See what investors are saying lately about Ventripoint: https://ceo.ca/vptVentripoint Diagnostics
(TSXV: VPT) (OTC Pink: VPTDF)[Suppressed Sound Link]Cannot view this video? Visit:
https://www.youtube.com/watch?v=JPTd0JGAWs8Tune in to 'Inside the Boardroom' each week and be part of the conversation that's shaping the business landscape. Visit CEO.CA or our YouTube page for hundreds more executive interviews from CEO.CA here.Interested in showcasing your company on 'Inside the Boardroom'? Get in touch with our team at sales@ceo.ca for further details and opportunities.About CEO.CAThe leading community for investors & traders in junior resource & venture stocks. CEO.CA is one of the most popular free financial websites and apps in Canada and for small-cap investors globally -- with industry leading audience engagement and mobile functionality. Since 2012, CEO.CA has brought millions of investors together from over 164 countries to discuss their portfolio holdings and find new investment opportunities. Download our App on iOS or Android marketplace or visit us today at CEO.CA to set up your free account. CEO.CA is a wholly owned subsidiary of EarthLabs, Inc. For further information please contact:CEO.CA
Email: hello@ceo.ca
Website: CEO.CANeither the TSX Venture Exchange ("TSXV"), OTC Best Market "(OTCQX") nor its Regulation Services Provider (as that term is defined in the policies of the TSXV) accepts responsibility for the adequacy or accuracy of this release. Cautionary Statement The information regarding any issuer contained or referred to in any interviews conducted by CEO.CA has been furnished by such issuer directly, and neither CEO.CA nor any of its affiliates or principals assumes any responsibility for the accuracy or completeness of such information or for any failure by an issuer to ensure disclosure of events or facts which may affect the significance or accuracy of any such information.No stock exchange, securities commission or other regulatory authority has approved or disapproved the information contained herein. This news release contains forward-looking information which involves risks, uncertainties and other factors that could cause actual events, results, performance, prospects, and opportunities to differ materially from those expressed or implied by such forward-looking information. Forward-looking information in this news release may include, but is not limited to, the objectives, goals, future plans, statements regarding exploration results and exploration and/or development plans of companies featured on the CEO.CA platform. Factors that could cause actual results to differ materially from such forward-looking information include, but are not limited to, capital and operating costs varying significantly from estimates, the preliminary nature of metallurgical test results, delays in obtaining or failures to obtain required governmental, environmental or other project approvals, uncertainties relating to the availability and costs of financing needed in the future, changes in equity markets, inflation, fluctuations in commodity prices, delays in the development of projects, currency risk and the other risks involved in the applicable exploration and development industry, and those risks set out in the public documents of such companies filed on SEDAR or elsewhere from time to time. Undue reliance should not be placed on such information, which only applies as of the date of this news release, and no assurance can be given that such events will occur in the disclosed time frames or at all. CEO.CA disclaims any intention or obligation to update or revise any forward-looking information, whether as a result of new information, future events or otherwise, other than as required by law.To view the source version of this press release, please visit https://www.newsfilecorp.com/release/285486
Original: CEO.CA's Inside the Boardroom: Why Ventripoint is the Most Profitable "Bolt-On" Solution for Modern Hospitals

Looks "under the radar"worthy

ASCEND Cardiovascular to Market and Distribute Ventripoint's AI-powered Heart-Scanning Technology to North American Hospitals and Clinics
V.VPT | 1 day ago
(TheNewswire)

Ventripoint Diagnostics Ltd.

Highlights of agreement

ASCEND’s IT software is used by 50,000 hospitals, clinics, and caregivers.

Initial two-year term for North American markets.

Ventripoint will be integrated into ASCEND’s IT for cardiovascular care.

Toronto, Ontario – TheNewswire - December 12, 2023 - Ventripoint Diagnostics Ltd. ("Ventripoint" or the "Company"), (TSXV:VPT)(OTC:VPTDF), now bringing its AI-powered heart-scanning technology to the world’s hospitals, is pleased to announce it has entered into a global distribution and marketing agreement with ASCEND Cardiovascular (“ASCEND”).

ASCEND Cardiovascular is a leader in offering cutting-edge diagnostic, and imaging technologies and workflows to improve cardiac health care. ASCEND is trusted by AGFA Healthcare, Sectra, Oracle/ Cerner, and other major players in the healthcare system. Its technology stack has been integrated into the workflows of 1,000+ top-ranked healthcare facilities and 600+ health systems, representing a user base of 50,000 who serve millions of heart patients.

ASCEND will market and distribute Ventripoint’s AI-powered heart-scanning technology, which turns ultrasound images of the heart into MRI-quality heart images. Using AI, and the images from existing ultrasound systems of any brand, Ventripoint creates these MRI-quality heart images at a fraction of the cost and time needed for more traditional heart MRIs. “After many years of careful research and development, and rigorous in-hospital testing, Ventripoint’s heart-imaging technology with ASCEND’s proven support is ready for the world’s hospitals and heart patients,” said Dr. Alvira Macanovic, President & CEO of Ventripoint. “With this ASCEND partnership I am encouraged we will win the confidence of hospitals and cardiologists across North America and beyond.”

“We are looking forward to the partnership between Ventripoint Diagnostics and ASCEND Cardiovascular. Our aim is that by working together, we can ultimately provide reliable and effective tools for clinicians on a global scale,” stated Jeffrey Soble, MD, ASCEND’s President and CEO.

The global distribution agreement has an initial two-year term, with ASCEND as the official reseller. ASCEND will market and sell the Ventripoint VMS+ system as part of its inclusive solution, as well as integration with ASCEND’s cardiovascular IT platform.

Ventripoint will be providing support and training to ASCEND on the use and capabilities of the VMS+ during the term of the agreement. The collaboration between Ventripoint and ASCEND will reduce time to market and overall effort to provide new software solutions to the market.

“Combining these two products creates an end-to-end solution rivaling the best technology offered on the market, said Dr. Macanovic. “Our partnership includes joint research and development initiatives to optimize current technologies and exploratory projects to identify new treatment possibilities, reduce waiting times, and ensure a cost-effective addition to the heart healthcare system.”

Ventripoint, now commercializing its technology, has won accolades from leading hospitals, and the British Heart Foundation and has drawn international media attention. As the relationship between Ventripoint and ASCEND Cardiovascular continues to evolve, both companies remain committed to driving innovation and excellence in cardiovascular health technology.

About Ventripoint Diagnostics Ltd.

Ventripoint has become an industry leader in the application of AI (Artificial Intelligence) to echocardiography. Ventripoint's VMS products are powered by its proprietary KBR technology, which is the result of a decade of development and provides accurate volumetric cardiac measurements equivalent to MRI. This affordable, gold-standard alternative allows cardiologists greater confidence in the management of their patients. Providing better care to patients serves as a springboard and basic standard for all of Ventripoint's products that guide our future developments. In addition, VMS+ is versatile and can be used with all ultrasound systems from any vendor supported by regulatory market approvals in the U.S., Europe, and Canada. Learn more: www.ventripoint.com.

About ASCEND Cardiovascular

ASCEND Cardiovascular is a leader in innovating cardiovascular solutions that empower the provider community to improve cardiovascular care. Designed with openness in mind, our solutions integrate with EHRs, medical devices, and other systems to deliver seamless workflows that span procedure types and modalities. A complete cardiovascular solution, ASCEND provides structured reporting, image visualization, collaboration, and analytics that improve efficiency, outcomes, and ROI. With decades of experience and a practicing cardiologist at our helm, the ASCEND team brings unparalleled “know how” in cardiology workflow, collaboration, and IT offering limitless opportunities to improve clinical, operational, and quality performance. Learn more: www.ascendcv.com.

For further information, please contact:

Jonathan Robinson CFA

JRobinson@oakhillfinancial.ca

(416) 669-1001

Neither the TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this news release.

Bounce !

LOOKS good volume nothing and green

We’re back to fifty

Fifty cents week now

PPS high over 49 cents today !

Fifty cents soon guaranteed !!

Fifty cents this week !!!!!!

Back to forty soon

Replaces MRI would be doctors buying this stock

More green fifty cents soon

Price moving green just slow dollar coming

I am very impressed with what Adams has done with this company. If Covid hadn't hit, this stock might have been close to a dollar by now. Here is a zoom interview/update that is very informative:
Highly recommend watching it! Their machine will be used in the pet industry, mainly dogs, and they're also talking about using it on horses! Dollars coming!!

Well, they are trading again. Not much excitement though. Put in a low bid but didn't get filled. Pretty good volume at 730k.

More News with attachments probably on the website: https://www.ventripoint.com

Dear Friend;

It has been a long time coming but we are back! or almost there as you will read in the attached news release. Here is some background:

1. The Company asked to have its stock halted December 12, 2019 - we were NOT suspended by the Exchange.
2. We received approval to stay halted until we completed the $1,220,000 private placement, which we did last Friday. No one expected it to take so long but COVID-19 disrupted everyone’s plans.
3. The Company actually benefited overall from the pandemic, which you will read about, but briefly we had more access to cardiologist and received a lot of government support (like many other companies). This allowed us to make major changes to almost every aspect of the VMS+3.0 to lower the barrier to adoption, reduce manufacturing costs, accelerate analysis and rewrite the entire source code. The key initiatives attachment is a long read (5 pages), but worth the time.
4. The major advantage of all this work is we no longer have to go to a hospital to install the machine, calibrate the probes and train the staff. It is all done remotely now. You will read about all the advantages this approach has created for us and our customers.
5. The hospitals, while focused on COVID, did continue in their processes to acquire a VMS+3.0 and so we have 11 major hospitals ready to acquire a system as soon as they re-open their echo labs. This is starting to happen as hospitals have to start dealing with regular cardiac patients.
6. We now know COVID wrecks havoc with the heart, especially the right side, and so cardiologists are very interested in our capabilities as they fear the heart problems induced by COVID could go on for decades.
7. Lots more news to come and lots more information on what we have been doing and why it is important on our revamped website and in the addendum..
8. We are in the final stages of the TSXV Exchange review to allow us to resume trading and so I expect that will happen very soon.

I am very thankful for all the people who encouraged me to keep going. It has not been a lot of fun, but we are in a very good place right now - a way ahead of where we were before we restructured. Our team has done remarkable things in the last 9 months and the responses we are seeing from cardiologists are reflecting that we have finally gotten through all the barriers to adoption with a device that is user-friendly and fits perfectly into the workflow of an echocardiography lab. I look forward to telling you all about the wonderful effects doctors with the VMS+3.0 are having on their patients, as well as how well the company is progressing to build value for its shareholders.

As usual, I thank you for your support and interest and if you have any questions or comments, email, text, call.

Regards,

Dr. George Adams ICD.D
Executive-Chairman
Ventripoint Diagnostics Ltd.

Ok It are 6 mio extra shares as warrants
But it could be much much more

The announcement will tell us a lot

If really good we could go to 0.4
If fluff we stay at 0.05

Yes, I've been on an email list from Adams. There was a PR attached to the email. It is probably at their website. I'm kinda concerned about the convertible debentures that made up this $1.22M offering. Toxic financing?? It's explained in the PR but it is greek to me.

Did you get that letter of him?
Great
Looking forward to the PR before trading resumes

Here is the email I received just now:

Attached is the news release for today documenting we have closed the second tranche of $495,000 of the private placement to complete the round (which we announced many months ago) with total gross proceeds of $1,220,000.

Here is some background:

1. The Company halted trading and ceased operations in December 2019 to restructure with a new Board and the return of Dr. Adams as acting CEO.
2. The Company closed a first tranche of the $1,220,000 financing February 9 ,2020 with proceeds of $725,000 and resumed operations with all key employees returning to work.
3. In March 2020, COVID-19 pandemic reached Canada and Company ceased manufacturing and fulfillment of orders to hospitals as hospitals were focused on COVID-19 operations.
4. The Company has been focused on eliminating barriers to adoption and enabling remote installation and training.
5. As of Sept 11, 2020 the Company has closed its financing with the remaining $495,000 of proceeds and now has the funds to fulfill its existing and forthcoming purchase orders (more about this in next NR).
6. The Company is in a “Resumption Review” with the TSXV Exchange and expects to be trading in the next few days and will provide a comprehensive corporate update prior to the resumption of trading.

As usual, if you have questions call me.

Regards,

Dr. George Adams ICD.D
Executive-Chairman
Ventripoint Diagnostics Ltd.

Depending on the opening price it would advise you
To enter as soon as possible after opening... if partnership
With a big one is announced!

Like Adams said, there are shareholders who want to get out, too. I'm curious as to what price the MMs will open trading at. Looks like the last trade was around a penny. I just found this company so I have no shares. Naturally I'd like to see it open as low as possible in order to get a good starter position. I think a partnership with a biggie is one of the announcements coming. Also, maybe an equipment upgrade or improvement. This is very similar to Lexagene, a medical device company, just starting commercialization. Even the price point of $50,000 is the same before discounts.

Yes indeed

The video is impressive

You noticed following

George Adams expect a wild day (first trading day) like 3 years ago when it went from
0.10 to 0.9

Tony mentionned that several announcements will be made before trading
Will be resumed

What s your guess on news?

News on study on COVID
More sales
Partnership with us / European big company


Sp could go crazy depending on news (0.20-0.50)

I have 400k shares at 0.25 average

This company has turned itself around and is about ready to rock! They've already had installs in several locations. Here is an up-to-date video with Dr. Adams filmed on Sept. 9, 2020. Any day now, maybe Monday, it will start trading again.

Doesn't look good for the company. Here is their last press release: Toronto, Ontario, December 19, 2019 – Ventripoint Diagnostics Ltd. (“Ventripoint” or the “Company”, TSXV:VPT, OTCQB:VPTDF) wishes to clarify the news release of December 17, 2019.
The Company is not in receivership and it has not made an assignment under the Bankruptcy and Insolvency Act. The Company is organizing a private placement and expects to resume normal operations in the new year."

That, of course, was 8 months ago so they may be in bankruptcy by now. The 12/17/19 release describes their funding plan which must not have happened. Getting involved with China is BAD news especially when you have no money to defend your property. I will try to contact Adams and see if there is anything salvageable with this stock.

Sales pitches are demoed online now.

Trading might be another month off until the final financing close occurs, but at least the company has started work again.

Financing is progressing.

VPTDF Tier Change = OTCQB to Grey Market

"I love trading halts because there is no news yet but I get to read the made up news of feeble minded posts from those who have persecution complex. It is so much fun watching them huddle together dependent on their fellow like-minded simpletons to pool their paranoid imaginations, discussing why they were born under a bad sign and someone has manipulated the sp downwards. etc."
Read more at https://stockhouse.com/companies/bullboard?symbol=v.vpt&postid=30447817#jvmMrTmytCxlClQq.99

Halted...another PP???

This Ventripoint video has never worked and stockdaymedia does not answer phone calls about it
https://stockdaymedia.com/news/radio-interviews/ventripoint-diagnostics-joins-everett-jolly-on-the-stock-day-podcast-vptdf-november-25-2019/

I was wondering if they’ll keep disclosing each sale or they’ll just put a nr when it’s a huge order. New CEO might change how they disclose them

Hopefully we get sales in the next week, since they have been to Europe a month ago.

New video. Explains why Justin L joined and that the tech integrates well with all devices on the market.

Thank you teq0904 for your thoughts on that!

Dear Friend;

As I wrote yesterday the FDA clearance (their word for approval) could come any day and it came late yesterday. Here is the news release and some background:

1. The US market is one of the largest single markets for medical devices in the world. We estimate that it would take 16,000 VMS+3.0 to deal with all the patients who get echocardiograms per year. This number is growing at 7% per year (1,000 system per year more each year) with an expectation of 25M people over 65 years by 2030.
2. We are now approved to market the VMS+3.0 so we can contact several major centres who have indicated they wanted to know as soon as the VMS+3.0 was clearance for clinical use.
3. The label remains the same that the VMS+3.0 can be used on "any patient where the results are warrants or desired”, which means all the attending doctor only needs is to desire the analysis be done to help with the diagnosis or monitoring.
4. I remind you the VMS+3.0 is a portable device which can be added to any existing 2D ultrasound machine (GE, Phillips, Siemens, Toshiba, Samsung, Mindray…) and be operational in a few minutes. It now allows for patient movement during the exam and has a continuous user guide for the exam as well as the analysis. These features have made it very user friendly.
5. In addition, it is inexpensive to manufacture, which will allow us to offer it as “razor-razor blade” or per use sale to accelerate adoption.
6. FDA clearance helps us worldwide as everyone knows how difficult it is to get FDA approval.
7. This is a major milestone for the company, which has been a long time coming, but has finally arrived. The company is undervalued at $6M market cap. If we were a pharmaceutical company with a FDA-approved orphan drug for a $1B market we would be trading at 10-20 times this market cap. The news today should tell people we are a company with a large market opportunity.

There is nothing to hold up sales if he gets more marketing companies involved, and lots of studies have been done showing it helps diagnosis for different heart issues so hospitals should have keen interest as more of them purchase it and testify at conferences that it is great.
More studies are planned which will prove its use for other applications too.

Hi, thanks for all of the posts. Good news today on approval. Investors in US don't seem to know about this company yet.

I read in an older post that some aspects of the tech will take years for meaningful sales. Just getting into looking at this - may I ask your take on sales growth short term and long term?

Dear Friend;

Attached is the news release from today. Here is some background:

1. We have installed three VMS+3.0 systems in Western Canada - two in paediatric centres and one in an adult cardiac centre. They are being used clinically on patients, as well as for research to expand its applications. The customers report they are very pleased with the ease of use and analytical results. This is great to hear as we worked very hard to improve the usability of the VMS+3.0.
2. St. Michale's Hospital will be the fourth major cardiac centre to get a VMS+3.0 as it is built passed QC and we can walk it over to them any day now. In addition, the ultrasound technologist there has been helping us with improving the usability and so is fully trained already. They can use it as soon as we can get the IT folks to let us install it. The IT folks at hospitals are always busy and so usually the limiting factor in scheduling an install. We have worked with them before so it should be very soon.
3. We have two more VMS+3.0 systems built and ready to be installed in Eastern Canada - one in a paediatric hospital and one in an adult hospital. We are also expecting an order from another adult cardiac centre.
4. Our sales team was in Europe last week and did many demos. We expect orders from these centres soon, as well.
5. We continue to wait for the FDA response to our submission. Could be any day now.

It is a September 13 video. At 5:40 he says there are 8M contrast media echo procedures in the US every year, which is a billion$ business in itself. Meanwhile we are starting the 5th month waiting for the FDA eggheads to approve it. Maz hospital is expanding the study to 50 now, but the first 25 were right on point so success is guaranteed.

FDA drags on, for no reason. This is a minor issue and should have been checked off long ago, but GA said they continue to try to finish it.

Attached is the press release announcing our manufacturing facility has been certified and is shipping the first VMS+3.0 products to hospitals in western Canada.

Here is some background:

1. We announced back in June that we stop using a contract manufacturer, which we had used for VMS+2.0 and create an internal fabrication facility at our head office in Toronto.
2. This was possible as the VMS+3.0 is a much simpler and less-costly machine to fabricate due to the new tracking method which is a simple circuit board embedded in the adaptor for the ultrasound probe.
3. Of course we had to have the facility certified before we could begin to manufacture devices and this was achieved Thursday last week.
4. We have now fabricated the first two VMS+3.0 in this certified facility and will ship them tomorrow or Friday to fulfil the first two purchase orders, which were from a Heart Institute and a Children’s hospital in western Canada (their policies are not to allow third parties to name them in press releases).
5. This is major milestone for the company and its mission to improve cardiac care for children and adults.
6. It has been an amazing summer so far with Health Canada and European approvals for the VMS+3.0, the establishment of the new manufacturing centre and now first sales - all in under two months.
7. We have more orders coming soon from Canada and Europe will come back from vacation in September and again a number of sites have indicated they are ready to purchase the new system.
8. We are still awaiting US-FDA clearance and have been told the agency is working to complete their review as soon as possible. Again we have hospitals ready to acquire the VMS+3.0 as soon as it is approved in the USA.
9. Our Chinese partners are also advancing their sales pipeline and expect to have first sales very soon.

It has already taken longer for the FDA review these minor changes than when we got a major label change from one chamber to all 4.